Mabion

Biologics CDMO · Contract biomanufacturing

Overview

Pivoted from biosimilar developer (MabionCD20) to a contract development & manufacturing organization for biologics.

What they do

Mabion is a Warsaw Stock Exchange-listed biopharmaceutical company that has repositioned itself as a fully integrated biologics contract development and manufacturing organization (CDMO). From its GMP- and ISO-certified facility in Konstantynów Łódzki, Poland, it offers development and GMP manufacturing of monoclonal antibodies and other recombinant protein products, plus bioanalytics, sterile fill-finish, packaging and serialization for clinical and commercial supply.

Lead program & status

Mabion originally built its reputation as a biosimilar developer, with MabionCD20, a rituximab biosimilar for blood cancers, as its lead asset targeting EU and US approval. After commercial and regulatory headwinds, the company pivoted to a services model, monetizing its manufacturing capacity and expertise for third-party clients rather than primarily advancing its own pipeline. In support of that strategy, Mabion announced a CDMO collaboration with Sartorius to offer integrated, non-exclusive development and manufacturing services, and in 2025 ran initiatives such as an oncology services competition at the BIO International Convention to attract recombinant-protein cancer programs.

Why it matters

Mabion's pivot demonstrates how a hard-won biologics manufacturing capability can be repurposed into a sustainable CDMO business, giving European and global biotechs an additional source of antibody and protein manufacturing capacity.

FAQ

What is Mabion's current business model?

Mabion now operates primarily as a biologics CDMO, providing contract development and GMP manufacturing of monoclonal antibodies and recombinant proteins from its facility in Konstantynow Lodzki, Poland.

What was MabionCD20?

MabionCD20 was Mabion's lead biosimilar candidate, a rituximab biosimilar for blood cancers; the company has since shifted its strategic focus from proprietary biosimilar development toward CDMO services.

Does Mabion have manufacturing partnerships?

Yes. Mabion announced a non-exclusive CDMO collaboration with Sartorius to offer customers an integrated range of biopharmaceutical development and manufacturing services.

Company website / source ↗ Open the interactive map →